Top Page
BioArctic AB Class B
(Frankfurt:BIOA.B)
BioArctic AB Class B (BIOA.B) vs. iShares MSCI Sweden ETF (EWD)
BioArctic AB Class B Business Overview & Revenue Model
BioArctic AB Class B Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86B | 257.35M | 616.00M | 228.29M | 23.15M | 62.35M |
| Gross Profit | 1.81B | 230.37M | 526.37M | 153.97M | -31.92M | 12.11M |
| EBITDA | 1.21B | -165.13M | 295.29M | 4.22M | -126.42M | -74.58M |
| Net Income | 1.07B | -177.08M | 229.25M | -11.18M | -119.79M | -68.52M |
Balance Sheet | ||||||
| Total Assets | 2.33B | 1.11B | 1.19B | 858.31M | 897.73M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92B | 778.92M | 1.11B | 805.39M | 848.40M | 999.94M |
| Total Debt | 48.99M | 54.23M | 4.98M | 10.04M | 15.88M | 20.77M |
| Total Liabilities | 293.59M | 216.74M | 139.50M | 72.06M | 109.05M | 143.01M |
| Stockholders Equity | 2.04B | 894.94M | 1.05B | 786.24M | 788.68M | 907.30M |
Cash Flow | ||||||
| Free Cash Flow | 1.05B | -342.97M | 302.25M | -44.38M | -144.84M | -104.81M |
| Operating Cash Flow | 1.05B | -316.33M | 309.69M | -31.64M | -140.46M | -92.34M |
| Investing Cash Flow | -584.08M | 205.63M | -507.49M | -12.76M | -4.41M | -12.52M |
| Financing Cash Flow | 18.00M | 5.69M | 14.06M | -2.81M | -7.39M | -6.60M |
BioArctic AB Class B Technical Analysis
BioArctic AB Class B Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | kr25.79B | 24.13 | 72.22% | ― | 521.22% | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | €1.09B | ― | -41.54% | ― | ― | 0.57% | |
| ― | kr2.62B | ― | -55.23% | ― | -92.57% | -7.72% | |
| ― | kr3.33B | -3.77 | ― | ― | 20.12% | 40.54% | |
| ― | $1.83B | -6.27 | -28.70% | ― | 382.81% | 23.87% | |
| ― | kr592.94M | ― | -275.87% | ― | ― | 38.99% |
BioArctic AB Class B Corporate Events
Health Canada has authorized Leqembi (lecanemab) for treating early Alzheimer’s disease in patients with mild cognitive impairment or mild dementia. This approval marks a significant milestone as Leqembi is the first treatment in Canada targeting the disease’s underlying cause, potentially impacting the Alzheimer’s treatment landscape and offering new hope to patients and caregivers.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB has announced the formation of its Nomination Committee, which includes representatives from its three largest shareholders: Demban AB, Ackelsta AB, and The Fourth Swedish National Fund. This committee, representing a significant portion of the company’s shares and votes, will prepare proposals for the 2026 Annual General Meeting, impacting the company’s governance and strategic direction.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB has announced the first treatment of a patient with Leqembi in Finland, marking a significant milestone in its efforts to address early Alzheimer’s disease in the Nordics. The approval and implementation of Leqembi, which targets amyloid-beta protofibrils and amyloid plaque, represent a strategic advancement for BioArctic as it seeks to expand its impact in the pharmaceutical industry and provide new treatment options for Alzheimer’s patients.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB’s partner Eisai announced that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer’s treatment, has been recognized by TIME as one of the best innovations of 2025 in the Medical and Healthcare category. This recognition highlights the innovation’s impact on Alzheimer’s treatment and strengthens BioArctic’s position in the biopharmaceutical industry, potentially enhancing its market presence and stakeholder confidence.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB’s partner, Eisai, has launched Leqembi Iqlik, a subcutaneous injection for Alzheimer’s maintenance treatment in the U.S., offering a convenient at-home option for patients with early-stage Alzheimer’s. This development is expected to streamline treatment pathways, reduce healthcare resource demands, and enhance patient convenience, potentially strengthening BioArctic’s market position in Alzheimer’s therapies.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB’s partner Eisai announced that Leqembi® (lecanemab) has been approved for once every four weeks intravenous maintenance treatment for early Alzheimer’s disease by China’s National Medical Products Administration. This approval marks a significant advancement in Alzheimer’s treatment, as Leqembi is the only approved therapy targeting both amyloid plaque and protofibrils, potentially impacting the disease’s progression. The approval strengthens BioArctic’s market position and offers new opportunities for commercialization in China, benefiting stakeholders involved in Alzheimer’s disease treatment.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB announced that the Therapeutic Goods Administration (TGA) of Australia has approved Leqembi® for treating early Alzheimer’s disease in specific patient groups. This approval marks a significant milestone following a review process initiated by Eisai, BioArctic’s partner, after an initial rejection. The approval strengthens BioArctic’s and Eisai’s position in the Alzheimer’s treatment market, allowing them to expand their commercialization efforts, particularly in the Nordic region.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
Gunilla Osswald, CEO of BioArctic AB, has been named Uppsala University’s Alumnus of the Year 2025, acknowledging her visionary leadership and contributions to science and technology. This recognition highlights her role in developing lecanemab, a groundbreaking Alzheimer’s treatment, and underscores her influence as a role model, particularly for women in STEM fields, reinforcing BioArctic’s position as a leader in neurodegenerative disease research.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB announced that its founders, Lars Lannfelt and Pär Gellerfors, plan to divest a minor portion of their shareholdings. This move is part of the company’s regulatory obligations and may impact the company’s stock dynamics, though it is not expected to significantly alter its operational or strategic direction.
The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK347.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB’s partner, Eisai, has initiated a rolling submission of a Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik, a subcutaneous autoinjector for early Alzheimer’s disease treatment, under Fast Track status. This development could allow patients to receive treatment at home, offering a more convenient alternative to intravenous dosing, potentially reducing healthcare resource demands and streamlining Alzheimer’s treatment.
The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB, in partnership with Eisai, announced the FDA approval of Leqembi IQKLIK, a subcutaneous injection for maintenance dosing in early Alzheimer’s disease. This approval marks a significant advancement in Alzheimer’s treatment, offering a more convenient administration method that could enhance patient access and reduce healthcare resource demands, potentially improving the company’s market position and stakeholder value.
The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB reported a significant increase in royalties from Leqembi® and announced a new partnership with Novartis, which includes an upfront payment and potential future milestones. The company’s operations are bolstered by strong sales forecasts for Leqembi®, recent marketing authorizations, and promising study results, positioning them well in the neurodegenerative disease treatment market.
The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB has entered a collaboration and license agreement with Novartis Pharma AG, leveraging its BrainTransporter technology for potential neurodegeneration treatments. The deal includes a $30 million upfront payment, with potential future milestones and royalties, highlighting BioArctic’s strategic positioning in the neurodegenerative treatment market and its potential for further partnerships.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB’s partner Eisai has launched Leqembi in the EU, starting with Austria and Germany, following its approval by the European Commission as the first therapy targeting the underlying cause of Alzheimer’s disease. This launch marks a significant step in addressing the unmet need for treatments that slow the progression of Alzheimer’s, potentially impacting the company’s market position and providing new options for patients and healthcare providers.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB announced it will release its second quarter report for 2025 on August 28, followed by an audiocast and teleconference for investors, analysts, and media. This event will provide insights into the company’s financial performance and strategic direction, potentially impacting investor perceptions and market positioning.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
BioArctic AB announced that sales of Leqembi® totaled 23.1 billion yen in the second quarter of 2025, resulting in a significant royalty increase of approximately 280% compared to the previous year. The sales figures included a one-time stockpiling effect in China due to tariff risks, with global sales excluding this effect amounting to 17.8 billion yen. This financial performance underscores BioArctic’s strengthened market position and potential for future growth in the Alzheimer’s treatment sector.
BioArctic AB’s partner, Eisai, presented new data at the Alzheimer’s Association International Conference 2025, highlighting the efficacy and safety of lecanemab in treating early-stage Alzheimer’s disease. The findings from the phase 3 Clarity AD study and real-world evidence suggest that lecanemab can slow disease progression and maintain cognitive function over four years, with a consistent safety profile, offering promising long-term benefits for patients.